Literature DB >> 18162944

Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among Navajo and White Mountain Apache infants.

Katherine L O'Brien1, Angeline B David, Aruna Chandran, Lawrence H Moulton, Raymond Reid, Robert Weatherholtz, Mathuram Santosham.   

Abstract

We report the phase III trial efficacy of 7-valent pneumococcal conjugate vaccine against clinical and culture proven otitis media (OM) among Navajo and White Mountain Apache infants. Efficacy was -0.4% (95% CI: -19.4 to 15.6) for clinically-diagnosed OM, 5.1% (95% CI: -51.5 to 40.6) for severe OM, and 64% (95% CI: -34% to 90%) for vaccine serotype pneumococcal OM suggesting that this vaccine is efficacious for pneumococcal OM in this high risk population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18162944     DOI: 10.1097/INF.0b013e318159228f

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  18 in total

1.  Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.

Authors:  Alexander Kuhlmann; J-Matthias Graf von der Schulenburg
Journal:  Eur J Health Econ       Date:  2016-02-23

2.  Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B.

Authors:  Merit Melin; Hanna Jarva; Lotta Siira; Seppo Meri; Helena Käyhty; Merja Väkeväinen
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

3.  Impact of pneumococcal conjugate vaccines on microbial epidemiology and clinical outcomes of acute otitis media.

Authors:  Isabelle Hau; Corinne Levy; Laurence Caeymaex; Robert Cohen
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

4.  Pan-serotype Reduction in Progression of Streptococcus pneumoniae to Otitis Media After Rollout of Pneumococcal Conjugate Vaccines.

Authors:  Joseph A Lewnard; Noga Givon-Lavi; Daniel M Weinberger; Marc Lipsitch; Ron Dagan
Journal:  Clin Infect Dis       Date:  2017-11-13       Impact factor: 9.079

5.  Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.

Authors:  Amanda Jane Leach; Edward Kim Mulholland; Mathuram Santosham; Paul John Torzillo; Peter McIntyre; Heidi Smith-Vaughan; Nicole Wilson; Beth Arrowsmith; Jemima Beissbarth; Mark D Chatfield; Victor M Oguoma; Peter Stanley Morris
Journal:  BMC Pediatr       Date:  2021-03-08       Impact factor: 2.125

Review 6.  Impact of pneumococcal conjugate vaccination on otitis media: a systematic review.

Authors:  Sylvia Taylor; Paola Marchisio; Anne Vergison; Julie Harriague; William P Hausdorff; Mark Haggard
Journal:  Clin Infect Dis       Date:  2012-03-15       Impact factor: 9.079

7.  Pneumococcal conjugate vaccines and otitis media: an appraisal of the clinical trials.

Authors:  Mark A Fletcher; Bernard Fritzell
Journal:  Int J Otolaryngol       Date:  2012-06-03

8.  Pneumococcal conjugate vaccines for preventing acute otitis media in children.

Authors:  Alexandre C Fortanier; Roderick P Venekamp; Chantal Wb Boonacker; Eelko Hak; Anne Gm Schilder; Elisabeth Am Sanders; Roger Amj Damoiseaux
Journal:  Cochrane Database Syst Rev       Date:  2019-05-28

9.  Burden of acute otitis media in primary care pediatrics in Italy: a secondary data analysis from the Pedianet database.

Authors:  Paola Marchisio; Luigi Cantarutti; Miriam Sturkenboom; Silvia Girotto; Gino Picelli; Daniele Dona; Antonio Scamarcia; Marco Villa; Carlo Giaquinto
Journal:  BMC Pediatr       Date:  2012-11-29       Impact factor: 2.125

10.  Pneumococcal vaccination and otitis media in Australian Aboriginal infants: comparison of two birth cohorts before and after introduction of vaccination.

Authors:  Grant Austin Mackenzie; Jonathan Rhys Carapetis; Amanda Jane Leach; Peter Stanley Morris
Journal:  BMC Pediatr       Date:  2009-02-19       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.